Silence Therapeutics shares start at Buy from Jefferies, reflecting strong clinical data By Investing.com

On Monday, Silence Therapeutics (NASDAQ:SLN) received a positive outlook from Jefferies, as the firm initiated coverage on the biotechnology company’s stock with a Buy rating and a price target of $40.00. Jefferies highlighted the potential of the company’s lead siRNA candidate, which has shown significant efficacy in lowering Lp(a), a causal risk factor for cardiovascular disease, by more than 90%.

The analyst from Jefferies noted that key opinion leaders (KOLs) believe Silence Therapeutics’ siRNA candidate stands out due to its efficacy and the less frequent injections required compared to similar programs. This favorable profile positions the candidate to potentially tap into a market worth over $20 billion.

Additionally, the company’s second candidate for treating Polycythemia Vera (PV), a hematologic disease that affects approximately 100,000 patients in the United States, has demonstrated promising Phase 1 data. The ongoing progress and updates from both the Lp(a)-lowering program and the PV treatment are expected to act as near-term catalysts for the company throughout 2024.

The endorsement from Jefferies comes at a time when Silence Therapeutics is actively developing its pipeline. The company’s focus on RNA interference (RNAi) technology for the treatment of diseases with unmet medical needs has positioned it as a notable player in the biotech industry.

Investors and stakeholders in the biotechnology sector are keeping an eye on Silence Therapeutics as it advances its clinical programs. The company’s progress and potential market opportunities are anticipated to influence its stock performance in the near future.

In other recent news, Silence Therapeutics has made significant strides in the biotechnology sector with its drug development programs. The company reported positive trial results for zerlasiran and divesiran, prompting H.C. Wainwright and BMO Capital Markets to maintain their Buy and Outperform ratings respectively. The potential of these drugs to generate over $1 billion in annual revenue is seen as a key factor in these ratings.

Silence Therapeutics has also received a $2.0 million milestone payment from Hansoh Pharmaceutical Group Company Limited, marking the second milestone in their partnership to develop short interfering RNAs using Silence’s mRNAi GOLD™ platform. This financial boost signifies growth and progress in the firm’s research endeavors.

In terms of personnel changes, the company announced the retirement of board member Alistair Gray. Despite this change, the firm is expected to continue its development and potential commercialization of its therapies, backed by a robust financial position with over $200 million expected to last into 2026.

InvestingPro Insights

As Silence Therapeutics (NASDAQ:SLN) garners attention with a positive outlook from Jefferies, investors may find additional context through InvestingPro data and tips. With a market capitalization of $893.37 million and a high Price / Book multiple of 6.05 as of the last twelve months leading up to Q2 2024, the company is trading at a valuation that reflects investor optimism about its future prospects. Despite a notable year-over-year revenue decline of 37.44%, the company’s liquid assets surpass its short-term obligations, providing financial flexibility as it continues to develop its siRNA candidate and other clinical programs.

According to InvestingPro Tips, Silence Therapeutics holds more cash than debt, which is a positive sign for financial stability. However, analysts do not expect the company to be profitable this year, reflecting the typical high research and development costs associated with the biotech industry. This is underscored by the company’s negative return on assets of -28.51% in the same period. On the brighter side, the company has experienced a significant return over the last year, with a price total return of 124.59%, showcasing the market’s strong response to its potential.

For investors seeking a deeper dive into Silence Therapeutics’ financials and market performance, there are additional InvestingPro Tips available at https://www.investing.com/pro/SLN. These tips could provide further insights into the company’s valuation and potential investment risks and opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.